ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2024
Last Updated on 02 Jan 2024
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion, in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin and prednisone, for previously untreated diffuse large B-cell lymphoma (DLBCL) with an international prognostic index (IPI) score of 3 to 5.

Funding status

Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indication from 1 March 2024.

MAF assistance does not apply to previously untreated diffuse large B-cell lymphoma in patients with an IPI score below 3.

Clinical indications, subsidy class and MediShield Life claim limits for polatuzumab vedotin are provided in the Annex.


Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma (Published 2 Jan 2024) PES Polatuzumab vedotin for previously untreated diffuse large B cell lymphoma (Published 2 Jan 2024)